Literature DB >> 19890000

Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.

Jie Luo1, Palmer Taylor, Mario Losen, Marc H de Baets, G Diane Shelton, Jon Lindstrom.   

Abstract

The main immunogenic region (MIR) is a conformation-dependent region at the extracellular apex of alpha1 subunits of muscle nicotinic acetylcholine receptor (AChR) that is the target of half or more of the autoantibodies to muscle AChRs in human myasthenia gravis and rat experimental autoimmune myasthenia gravis. By making chimeras of human alpha1 subunits with alpha7 subunits, both MIR epitopes recognized by rat mAbs and by the patient-derived human mAb 637 to the MIR were determined to consist of two discontiguous sequences, which are adjacent only in the native conformation. The MIR, including loop alpha1 67-76 in combination with the N-terminal alpha helix alpha1 1-14, conferred high-affinity binding for most rat mAbs to the MIR. However, an additional sequence corresponding to alpha1 15-32 was required for high-affinity binding of human mAb 637. A water soluble chimera of Aplysia acetylcholine binding protein with the same alpha1 MIR sequences substituted was recognized by a majority of human, feline, and canine myasthenia gravis sera. The presence of the alpha1 MIR sequences in alpha1/alpha7 chimeras greatly promoted AChR expression and significantly altered the sensitivity to activation. This reveals a structural and functional, as well as antigenic, significance of the MIR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19890000      PMCID: PMC2787250          DOI: 10.1523/JNEUROSCI.2833-09.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  55 in total

1.  The crystal structure of the Fab fragment of a rat monoclonal antibody against the main immunogenic region of the human muscle acetylcholine receptor.

Authors:  M Kontou; D D Leonidas; E H Vatzaki; P Tsantili; A Mamalaki; N G Oikonomakos; K R Acharya; S J Tzartos
Journal:  Eur J Biochem       Date:  2000-04

2.  Risk factors for acquired myasthenia gravis in cats: 105 cases (1986-1998).

Authors:  G D Shelton; M Ho; P H Kass
Journal:  J Am Vet Med Assoc       Date:  2000-01-01       Impact factor: 1.936

3.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.

Authors:  K Brejc; W J van Dijk; R V Klaassen; M Schuurmans; J van Der Oost; A B Smit; T K Sixma
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Asymmetric structural motions of the homomeric alpha7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation.

Authors:  Richard H Henchman; Hai-Long Wang; Steven M Sine; Palmer Taylor; J Andrew McCammon
Journal:  Biophys J       Date:  2003-11       Impact factor: 4.033

5.  Structural and ligand recognition characteristics of an acetylcholine-binding protein from Aplysia californica.

Authors:  Scott B Hansen; Todd T Talley; Zoran Radic; Palmer Taylor
Journal:  J Biol Chem       Date:  2004-04-06       Impact factor: 5.157

6.  Spontaneous remission in canine myasthenia gravis: implications for assessing human MG therapies.

Authors:  G D Shelton; J M Lindstrom
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

7.  Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations.

Authors:  Scott B Hansen; Gerlind Sulzenbacher; Tom Huxford; Pascale Marchot; Palmer Taylor; Yves Bourne
Journal:  EMBO J       Date:  2005-09-29       Impact factor: 11.598

8.  Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line.

Authors:  Philip J Reeves; Nico Callewaert; Roland Contreras; H Gobind Khorana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

9.  Role of tolerogen conformation in induction of oral tolerance in experimental autoimmune myasthenia gravis.

Authors:  S H Im; D Barchan; M C Souroujon; S Fuchs
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

10.  Tryptophan fluorescence reveals conformational changes in the acetylcholine binding protein.

Authors:  Scott B Hansen; Zoran Radic'; Todd T Talley; Brian E Molles; Tom Deerinck; Igor Tsigelny; Palmer Taylor
Journal:  J Biol Chem       Date:  2002-09-13       Impact factor: 5.157

View more
  29 in total

1.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

2.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

Review 3.  Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine.

Authors:  John A Dani
Journal:  Int Rev Neurobiol       Date:  2015-08-21       Impact factor: 3.230

4.  Precision medicine for autoimmune disease.

Authors:  Lucienne Chatenoud
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

Review 5.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

6.  Agonist Selectivity and Ion Permeation in the α3β4 Ganglionic Nicotinic Receptor.

Authors:  Anant Gharpure; Jinfeng Teng; Yuxuan Zhuang; Colleen M Noviello; Richard M Walsh; Rico Cabuco; Rebecca J Howard; Nurulain T Zaveri; Erik Lindahl; Ryan E Hibbs
Journal:  Neuron       Date:  2019-09-02       Impact factor: 17.173

Review 7.  In pursuit of the high-resolution structure of nicotinic acetylcholine receptors.

Authors:  Lin Chen
Journal:  J Physiol       Date:  2009-12-07       Impact factor: 5.182

8.  Myasthenogenicity of the main immunogenic region.

Authors:  Jon Lindstrom; Jie Luo
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

9.  MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4.

Authors:  Maartje G Huijbers; Wei Zhang; Rinse Klooster; Erik H Niks; Matthew B Friese; Kirsten R Straasheijm; Peter E Thijssen; Hans Vrolijk; Jaap J Plomp; Pauline Vogels; Mario Losen; Silvère M Van der Maarel; Steven J Burden; Jan J Verschuuren
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis.

Authors:  Jie Luo; Jon Lindstrom
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.